No Data
No Data
Some Shareholders Feeling Restless Over Sichuan Goldstone Asia Pharmaceutical Inc.'s (SZSE:300434) P/S Ratio
Sichuan Goldstone (300434.SZ): Does not involve the production of PBO materials
Goldstone Pharmaceuticals (300434.SZ) stated on the investor interaction platform on September 12 that the company is not involved in the production of PBO materials and is currently conducting research and development work on vacuum coating equipment for the surface metallization treatment of PBO materials.
We Think You Can Look Beyond Sichuan Goldstone Asia Pharmaceutical's (SZSE:300434) Lackluster Earnings
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Sichuan Goldstone Pharmaceuticals (300434.SZ) released its performance for the first half of the year, with a net income of 39.2022 million yuan, a decrease of 74.83%.
Sichuan Goldstone (300434.SZ) released its 2024 interim report, and the company's revenue was 0.522 billion...
No Data
No Data